Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology

Ravindran Kanesvaran(University of Ioannina), Vincent Launay‐Vacher(Sorbonne Université), Robert J. Motzer(Privolzhsky Research Medical University), Toni K. Choueiri(Dana-Farber Cancer Institute), Olivia Le Saux(Hospices Civils de Lyon), Florian Scotté(University of Derby), Joaquim Bellmunt(Radboud University Nijmegen)
The Lancet Oncology
June 1, 2018
10.1016/s1470-2045(18)30125-6
Cited by 62

Related Papers

The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k